A Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-236A and AD-236B
NCT07730567
Diabete Type 2, Diabetes Mellitus
Seoul, South Korea
View Trial DetailsNCT Number: NCT06117449
Diabetes mellitus is an endocrine disorder with heterogeneous etiologies, which is characterized by raised levels of glucose in a person's blood and disturbances of macromolecules such as carbohydrate, fat, and protein metabolism resulting from defects in insulin secretion, insulin action, or both.
A lack of insulin, or the inability of cells to respond to it, leads to high levels of blood glucose (hyperglycemia), which is the clinical indicator of diabetes. Type 1 DM is characterized by insulin deficiency and a tendency to develop diabetic ketoacidosis, whereas type 2 DM is characterized by variable degrees of insulin resistance, impaired insulin secretion, and excessive hepatic glucose produc Tion. Diabetes is one of the most rapidly increasing chronic diseases and an important public health problem all over the world. The global burden of diabetes is rising dramatically worldwide. Type 2 diabetes is the most common type of diabetes, accounting for around 90% of all diabetes worldwide (IDF). The prevalence of type 2 diabetes is high and rising across all regions. This rise is driven by increasing life expectancy, economic development, and increasing urbanization leading to more sedentary lifestyles and greater consumption of unhealthy foods linked with obesity.
Type 2 diabetes prevalence has increased in Egypt during the past few years. Egypt is one of the top ten nations with the greatest proportion of adults with diabetes, according to the International Diabetes Federation. In Egypt, the prevalence of diabetes was projected to be 9.6 million, with type 2 diabetes making up the bulk of cases .
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
-Patients with type 2 diabetes mellitus aged ≥18 years.
Criteria:
Exclusion criteria
Time frame: baseline
comparison of blood glucose level on patients who going on insulin therapy with patient going on oral antidiabetic
Time frame: baseline
comparison of HbA1C level on patients who going on insulin therapy with patient going on oral antidiabetic
Contact information is provided by the study sponsor or research team.
Assiut University
Other
Effectiveness and Satisfaction of Insulin Therapy in Type 2 Diabetic Patients (Real Life Study)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07730567
Diabete Type 2, Diabetes Mellitus
Seoul, South Korea
View Trial DetailsNCT07713836
Body Weight, Diabete Type 2
Dallas, Texas, United States
View Trial DetailsNCT07563699
Diabete Type 2, Diabetes Mellitus
Tel Aviv, Israel
View Trial DetailsNCT07619677
Cardiovascular Diseases, Diabete Type 2
View Trial Details